AIDS

1. BYRD KK, Tie Y, Lin CY, Kuo Y, et al
   Estimated major adverse cardiovascular events averted among persons with HIV if treated with a moderate-intensity statin.
   AIDS. 2025 Oct 16. doi: 10.1097/QAD.0000000000004385.
   

   >> Share

   
   

   
   AIDS Res Hum Retroviruses

2. AYTEKIN M, Elmaslar Mert HT
   Late HIV Diagnosis in Thrace, Turkey: A Six-Year Experience from a Border Region.
   AIDS Res Hum Retroviruses. 2025 Oct 16. doi: 10.1177/08892229251388414.
   

   >> Share

   
   

   
   Am J Epidemiol

3. OLIVEIRA ROSTER KI, Ronn MM, Elder H, Gift TL, et al
   Estimating the undetected burden and the likelihood of strain persistence of drug-resistant Neisseria gonorrhoeae.
   Am J Epidemiol. 2025;194:2861-2869.
   

   >> Share

   
   

   
   BMC Cancer

4. TESFOM HN, Gizaw M, Yilam M, Klein JMA, et al
   Prevalence and factors associated with high-risk human papillomavirus infection and cervical lesions among women with HIV in Addis Ababa, Ethiopia.
   BMC Cancer. 2025;25:1557.
   

   >> Share

   
   

   
   Clin Infect Dis

5. AJIBOLA G, Nelson BS, Niesar A, Hong S, et al
   Long-term clinical, immunologic, and viral reservoir outcomes in children treated with VRC01LS and 10-1074 monoclonal antibodies in the Tatelo Study.
   Clin Infect Dis. 2025 Oct 13:ciaf568. doi: 10.1093.
   

   >> Share

   
   
6. LEE YT, Chen SC
   Weight Trajectories with Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort.
   Clin Infect Dis. 2025 Oct 13:ciaf570. doi: 10.1093.
   

   >> Share

   
   
7. MULENGA H, Shenje J, Mendelsohn SC, Luabeya AKK, et al
   Asymptomatic Tuberculosis in Children with Household Exposure to Mycobacterium tuberculosis.
   Clin Infect Dis. 2025 Oct 15:ciaf562. doi: 10.1093.
   

   >> Share

   
   
8. ALLAN-BLITZ LT, Mayer KH
   The 2025 Centers for Disease Control and Prevention Non-Occupational HIV Post-Exposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions.
   Clin Infect Dis. 2025 Oct 15:ciaf567. doi: 10.1093.
   

   >> Share

   
   
9. MOONAN PK, Buff A, Nandakumar S, Morris Bamrah S, et al
   C-reactive protein in TB meningitis: signal, surrogate, or saboteur?
   Clin Infect Dis. 2025 Oct 16:ciaf575. doi: 10.1093.
   

   >> Share

   
   
10. ATIEH O, Daher J, Abboud M, Wu Q, et al
    Effects of Semaglutide on Cognitive Function in People with HIV: A Randomized Controlled Trial.
    Clin Infect Dis. 2025 Oct 16:ciaf577. doi: 10.1093.
    

    >> Share

    
    
11. LE JN, Zhu W, Huang YA, Wei W, et al
    Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015-2023.
    Clin Infect Dis. 2025 Oct 16:ciaf581. doi: 10.1093.
    

    >> Share

    
    

    
    HIV Med

12. ARCOS-RUEDA MDM, Gil Garrote S, Torres Garcia EG, de Gea Grela A, et al
    Trends in acute hepatitis B among people living with HIV over 25 years: Incidence and clinical outcomes.
    HIV Med. 2025 Oct 15. doi: 10.1111/hiv.70132.
    

    >> Share

    
    
13. ZHAO Y, Fu X, Yang Y, Shi L, et al
    Comorbidities, comedications and potential drug-drug interactions among people living with HIV in China.
    HIV Med. 2025 Oct 16. doi: 10.1111/hiv.70127.
    

    >> Share

    
    
14. O'REILLY M, Wohl DA, Hall S, Canijta EJP, et al
    A community and clinical collaboration to optimize HIV treatment and care for people with HIV in Australia-Solutions from the Beyond Undetectable symposium.
    HIV Med. 2025 Oct 15. doi: 10.1111/hiv.70110.
    

    >> Share

    
    
15. 
    Abstracts of the 20th European AIDS Conference 2025, October 15-18, 2025, Paris, France.
    HIV Med. 2025;26 Suppl 4:5-701.
    

    >> Share

    
    
16. 
    Abstracts of the 20th European AIDS Conference 2025, October 15-18, 2025, Paris, France.
    HIV Med. 2025;26 Suppl 4:702-763.
    

    >> Share

    
    
17. AMBROSIONI J, Levi LI, Alagaratnam J, Sempere A, et al
    Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025.
    HIV Med. 2025 Oct 15. doi: 10.1111/hiv.70120.
    

    >> Share

    
    
18. BORRAS-BLASCO J, Valcuende-Rosique A, Cornejo-Uixeda S
    Letter to the editor on "Effectiveness, safety and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study".
    HIV Med. 2025 Oct 13. doi: 10.1111/hiv.70071.
    

    >> Share

    
    
19. MCQUILLAN O, Carnes L, Croston M, Delaney J, et al
    HIV-related stigma mandatory training in healthcare-carrot versus stick.
    HIV Med. 2025 Oct 13. doi: 10.1111/hiv.70124.
    

    >> Share

    
    
20. SYAMSIR SB, Setiawan A, Natashia D, Purwati NH, et al
    "I cry alone because I'm so exhausted": Family caregivers' perspectives on mHealth support in paediatric HIV care in Indonesia.
    HIV Med. 2025 Oct 12. doi: 10.1111/hiv.70126.
    

    >> Share

    
    
21. FAGGIANO T, Yin J, Patel N, Karim A, et al
    Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy.
    HIV Med. 2025 Oct 12. doi: 10.1111/hiv.70128.
    

    >> Share

    
    

    
    Int J Cancer

22. YU X, Nzoutchoum OL, Gao D, Hsu CD, et al
    Cervical cancer screening and prevalence among older US Medicare beneficiaries with and without HIV.
    Int J Cancer. 2025 Oct 13. doi: 10.1002/ijc.70193.
    

    >> Share

    
    
23. CHINULA L, Chagomerana MB, Mkochi T, Msowoya L, et al
    Single visit screen-triage-treat strategy using GeneXpert-based HPV testing of self-collected cervicovaginal samples and thermal ablation treatment for cervical cancer prevention among women in Lilongwe, Malawi.
    Int J Cancer. 2025 Oct 16. doi: 10.1002/ijc.70177.
    

    >> Share

    
    

    
    J Acquir Immune Defic Syndr

24. HSUE PY, Behrens GMN, Xu ZJ, Zhao Y, et al
    Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score Model After Continuing or Switching to a Doravirine-Based HIV Treatment Regimen.
    J Acquir Immune Defic Syndr. 2025 Oct 13. doi: 10.1097/QAI.0000000000003778.
    

    >> Share

    
    
25. MCHENRY MS, Huo Y, Williams PL, Patel K, et al
    Plasma inflammatory biomarkers lack strong association with cognitive outcomes among young adults with perinatal HIV exposure and/or acquisition.
    J Acquir Immune Defic Syndr. 2025 Oct 14. doi: 10.1097/QAI.0000000000003771.
    

    >> Share

    
    

    
    J Am Acad Dermatol

26. AKISKA YM, Byrne M, Nasseri M, Koay A, et al
    Prevalence, incidence, and risk factors for dermatologic conditions in people with HIV in the modern antiretroviral era: A cohort study in Washington, DC.
    J Am Acad Dermatol. 2025 Oct 14:S0190-9622(25)02804.
    

    >> Share

    
    

    
    J Clin Immunol

27. ALIYEVA G, Bajin IY, Orhan D, Kutluk T, et al
    Epstein-Barr Virus-Associated Smooth Muscle Tumors in inborn Errors of Immunity: A single-center Case Series and Literature Overview.
    J Clin Immunol. 2025;45:144.
    

    >> Share

    
    

    
    J Virol

28. HUANG S, Zhao Y, Phillips S, Warrick JE, et al
    Single-base m(6)A epitranscriptomics reveals novel HIV-1 host interaction targets in primary CD4(+) T cells.
    J Virol. 2025 Oct 14:e0153625. doi: 10.1128/jvi.01536.
    

    >> Share

    
    

    
    JAMA

29. CHEVALIER FJ, Bacon O, Johnson KA, Cohen SE, et al
    Syphilis: A Review.
    JAMA. 2025 Oct 16. doi: 10.1001/jama.2025.17362.
    

    >> Share

    
    

    
    Lancet

30. BEKKER LG, Joseph Davey D, Saidi F
    Two for two: lenacapavir during pregnancy and lactation.
    Lancet. 2025;406:1560-1561.
    

    >> Share

    
    
31. 
    Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    

    >> Share

    
    
32. 
    Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    

    >> Share

    
    
33. 
    Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917.
    

    >> Share

    
    

    
    Nat Med

34. RAMGOPAL MN, Lalezari JP, Pires Dos Santos AG, Krishnan P, et al
    Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study.
    Nat Med. 2025 Oct 15. doi: 10.1038/s41591-025-03993.
    

    >> Share

    
    

    
    PLoS Comput Biol

35. JOUBBI S, Micheli A, Milazzo P, Ciano G, et al
    Enhancing antibody-antigen interaction prediction with atomic flexibility.
    PLoS Comput Biol. 2025;21:e1013576.
    

    >> Share

    
    

    
    PLoS One

36. MLAMBO LM, Setlaleleng M, Shearer K, Mofokeng NJ, et al
    TB will never end because of us: Experiences of TB preventive treatment among people living with HIV/AIDS in South Africa.
    PLoS One. 2025;20:e0333367.
    

    >> Share

    
    
37. CHIVITE I, Guilera V, Callau P, Aguilo R, et al
    Results of a fast-track HIV and hepatitis C screening protocol in Barcelona, Spain.
    PLoS One. 2025;20:e0328464.
    

    >> Share

    
    
38. MA X, Bai R, Zhu Z, Wang T, et al
    Hepatotoxicity risk factors in HIV-infected MSM with HBV/HCV coinfections: A cohort study in Northwestern China.
    PLoS One. 2025;20:e0333371.
    

    >> Share

    
    

    
    Vaccine

39. RACCAGNI AR, Morsica G, Reali P, Lolatto R, et al
    Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.
    Vaccine. 2025;66:127825.
    

    >> Share

    
    
40. IVERSEN EF, Rahimic AHF, Frattari GS, Rosas-Umbert M, et al
    TCR bias drives development of dominant vaccine-induced CD8+ T cell responses which can be redirected toward cellular targets.
    Vaccine. 2025;66:127851.
    

    >> Share

    
    
41. COLLINS C, Ratshisusu L, Modise LM, Simani OE, et al
    Hepatitis B virus infection and vaccine coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.
    Vaccine. 2025;66:127843.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share